Clinical Trial Update: Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 biomarker-driven intermittent docetaxel trial in metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Conditions: Castration Resistant Prostatic Cancer | Phase 2 | Status: TERMINATED